2023 Life Sciences Industry and Real Estate Perspective: Part 1

Assess the future landscape for biopharma, medtech and biomanufacturing

JLL's Head Of Life Sciences, says "The 2023 report shows that market conditions in the life sciences this past year have been particularly volatile and have tested the mettle of even the most seasoned, experienced life sciences real estate professional."

In this report, we explore how to rethink and reshape the infrastructure necessary to make science possible. You will have the chance to both "look back" and "look ahead", cultivating a deeper level of understanding of what makes a healthy and vibrant life sciences ecosystem and the critical role real estate plays in fostering that ecosystem.

Key Takeaways:

1. Demand for lab space has slowed but is poised to bounce back as capital sources grow more confident in coming months.
2. A supply wave of lab space is hitting markets across the U.S., with higher concentration in Boston and the Bay Area.
3. Historical biotech downturns provide limited precedent, but positive signals are emerging.
4. Opportunities exist for tenants and landlords in a challenging environment.

Click here to explore Part 2 of this report and discover more information about the medtech and biomanufacturing markets.